efficacy of pd-l1 inhibitor avelumab in nepc/avpc
Published 3 years ago • 221 plays • Length 6:38Download video MP4
Download video MP3
Similar videos
-
3:39
pick-nepc: avelumab in nepc/avpc
-
2:07
efficacy of pd-1/pd-l1 inhibitors in melanoma
-
30:23
lecture looking ahead - potential barriers to immune checkpoint inhibitors use in mibc
-
3:50
testing the safety and efficacy of the pd-l1 antibody durvalumab
-
4:49
emerging pd-l1 inhibitors for hnscc
-
6:21
the emergence of pd-l1 inhibitors
-
2:12
cancer immunotherapy | the pd-l1 pathway
-
3:27
improving anti-pd-1/pd-l1 therapy for localized bladder cancer
-
0:36
immune checkpoint inhibitors: recent progress and potential biomarkers - 3ii pd-l1 overexpression
-
3:59
the selection of pd-l1 escape variants in microsatellite stable metastatic crc on avelumab treatment
-
23:02
immunotherapy: moving beyond pd1 and pdl1 inhibitors
-
0:51
dr. elizabeth plimack on ipilimumab and pd-l1 inhibitors in the treatment of bladder cancer
-
1:25
pd-1 and pd-l1 expression in esophageal and gastric cancer
-
0:46
immune checkpoint inhibitors: recent progress and potential biomarkers - 3iv pd-l1 overexpression
-
0:46
immune checkpoint inhibitors: recent progress and potential biomarkers - 3i pd-l1 overexpression
-
4:10
combination of medi0680, an anti-pd-1 antibody, with durvalumab, an anti-pd-l1 antibody
-
1:06
pd-l1: an important, but imperfect biomarker
-
1:16
explaining immunotherapy, pd-l1 and pd-1
-
0:58
immune checkpoint inhibitors: recent progress and potential biomarkers - 3iii pd-l1 overexpression